Cryoport Systems Wins “BioServices Innovation of the Year” for Safepak® Soft System 1800
Cryoport Systems is proud to announce that our Safepak® Soft System 1800 has been named BioServices Innovation of the Year by the prestigious BioTech Breakthrough Awards program. This recognition highlights our continued commitment to advancing cryogenic logistics for cell and gene therapy developers through innovation and excellence when it comes to safety and sustainability.
The BioTech Breakthrough Awards, now in their fifth year, honor excellence across the life sciences and biotechnology sectors. With thousands of nominations from over 15 countries, the program is a global platform that celebrates bold ideas and transformative technologies. Cryoport Systems’ win underscores the impact of our Safepak Soft System 1800 in solving persistent challenges in cryogenic transport, especially for high-value, fragile biologics.
A New Standard in Cryogenic Packaging
The Safepak Soft System 1800 is a secondary packaging solution engineered to protect cryopreserved blood bags and other biologic payloads during transit. At the heart of the system is our patent-pending SoftRack™ technology, a flexible insert that immobilizes and cushions payloads to virtually eliminate movement, vibration, and contact damage. This innovation directly addresses a critical vulnerability in conventional cryogenic transport systems, which often rely on rigid metal cassette racks that can cause shock and metal-to-metal contact, leading to potential payload compromise.
In addition to SoftRack, the system features an ultra-absorbent containment bag with an absorption capacity of up to 1,800 mL, offering superior protection against leakage or containment failure. The Safepak Soft System 1800 is engineered for thermal stability, maintaining cryogenic integrity across transit conditions to ensure both product quality and environmental safety.
Validated Compliance that Scales
The Safepak Soft System 1800 has been validated for use with the Cryoport Express® Cryogenic HV3 Shipping System and meets global shipping standards including UN3373, UN3245, and others. Its intuitive design simplifies packing procedures, reduces training time, and enhances operational efficiency while eliminating excess materials commonly found in traditional packaging solutions.
This combination of technical performance alongside regulatory readiness and user-centric design makes the Safepak Soft System 18000 a standout solution for biopharmaceutical companies, CDMOs, CROs, and clinical trial sponsors seeking to safeguard their advanced therapies in transit.
Industry Recognition and Impact
“We designed the Safepak Soft System 1800 to solve a critical weakness in conventional cryogenic transport systems,” said Michael Dybicz, SVP and Chief Product Development Officer at Cryoport Systems. “Our innovation delivers measurable benefits across safety, compliance, and workflow efficiency. Most importantly, it helps ensure critical therapies arrive intact and on time, especially for patients whose outcomes depend on the integrity of every shipment.”
Mark Sawicki, CEO of Cryoport Systems, added, “We’re thrilled to accept this award from BioTech Breakthrough. The Safepak Soft System 1800 demonstrates our commitment to not only solve persistent problems in cryogenic logistics, but also do so with a sustainable, scalable, and user-friendly design.”
Bryan Vaughn, Managing Director of BioTech Breakthrough, emphasized the significance of the innovation: “The Safepak Soft System 1800 sets a new standard for how cryogenic biologics are transported. For its unique combination of technical performance, regulatory readiness, environmental responsibility, and patient-focused impact, Cryoport Systems’ Safepak Soft System 1800 is our choice for ‘BioServices Innovation of the Year!’”
Enabling the Outcome™
Cryoport Systems continues to lead the way in temperature-controlled supply chain solutions for the life sciences, with a focus on regenerative medicine. Our integrated platform brings together the end-to-end supply chain within a single vendor model, supporting the safe and efficient delivery of life-saving therapies around the world.
This award reinforces our mission to Enable the Outcome™ by delivering solutions that minimize risk, maximize reliability, and prioritize patient outcomes. As the biotechnology sector evolves, Cryoport Systems remains at the forefront… developing innovations that meet the rigorous demands of modern biologics and cell and gene therapies.
